CN119817811B - Nutritional composition and use thereof - Google Patents
Nutritional composition and use thereof Download PDFInfo
- Publication number
- CN119817811B CN119817811B CN202510308140.3A CN202510308140A CN119817811B CN 119817811 B CN119817811 B CN 119817811B CN 202510308140 A CN202510308140 A CN 202510308140A CN 119817811 B CN119817811 B CN 119817811B
- Authority
- CN
- China
- Prior art keywords
- food product
- nutritional composition
- mfgm
- mlct
- fatty acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明涉及一种营养组合物及其用途。所述营养组合物包括中长链脂肪酸甘油三酯和乳脂肪球膜，其中所述中长链脂肪酸甘油三酯对所述乳脂肪球膜的重量比为0.1:1至50:1。本发明的营养组合物能够起到明显改善睡眠的作用。
The present invention relates to a nutritional composition and its use. The nutritional composition comprises medium-chain fatty acid triglycerides and milk fat globule membranes, wherein the weight ratio of the medium-chain fatty acid triglycerides to the milk fat globule membranes is 0.1:1 to 50:1. The nutritional composition of the present invention can significantly improve sleep.
Description
Technical Field
The present invention relates to the field of food and pharmaceutical products, in particular to a nutritional composition comprising medium-long chain fatty acid triglycerides and milk fat globule membranes, food and pharmaceutical products comprising the nutritional composition, the use of the nutritional composition or the food for non-therapeutic purposes for improving sleep, and the use of the nutritional composition for the manufacture of a medicament for improving sleep.
Background
The good sleep can help people to relieve physical strength, improve immune function and build cognitive ability, which is a necessary physiological requirement for people to survive. Especially for infants, the infants are in the key stage of growth and development, and good sleep condition is important for promoting physical growth, nervous system development and intelligence development. If the sleeping quality of the infants has serious problems, such as arousal or sleep rhythm disorder, the infants not only have influence on physical growth and intelligence development, but also have a certain influence on emotion and behavior. The sleep-wake pattern and sleep quality of the infant can to some extent influence the sleep quality and mood of the mother (Chen Jinshi. Early sleep intervention strategies have been studied for the effects of infant physical growth and sleep-wake pattern [ J ]. Journal of aerospace medicine, 2023,34 (04): 409-411).
In view of the above, it is important to develop a pathway capable of effectively improving sleep.
Disclosure of Invention
The present invention has been made keeping in mind the above problems occurring in the prior art.
In a first aspect, the present invention relates to a nutritional composition comprising medium-and long-chain fatty acid triglycerides (MLCT), and milk fat globule membranes (MFGM, milk Fat Globule Membrane, also commonly known as MFGM lactophospholipids), wherein the weight ratio of MLCT to MFGM is from 0.1:1 to 50:1.
The inventors have unexpectedly found in the study that MLCT and MFGM, when used in combination in a specific weight ratio, exhibit a synergistic effect in improving sleep, in particular in terms of the amount of wakefulness and the total time of wakefulness, the effect of the combined use being superior to that of the same total amount of MLCT alone, as well as to that of the same total amount of MFGM alone.
In a second aspect, the present invention relates to a food product comprising a nutritional composition according to the first aspect of the invention.
In a third aspect, the invention relates to a pharmaceutical product comprising a nutritional composition according to the first aspect of the invention.
In a fourth aspect, the present invention relates to the use of a nutritional composition according to the first aspect of the invention or a food product according to the second aspect of the invention for non-therapeutic purposes for improving sleep.
In a fifth aspect, the present invention relates to the use of a nutritional composition according to the first aspect of the invention for the preparation of a medicament for improving sleep.
Drawings
In order to more clearly illustrate the technical solution of the present invention, the drawings required for describing the embodiments will be briefly described below. It should be understood that these drawings are merely for the purpose of facilitating easier understanding of the present invention by the skilled person and are not intended to limit the scope of the present invention.
Fig. 1 presents the results of statistical analysis of the wakefulness of zebra fish (a and C) and the total wakefulness time (B and D) in the normal control group, the model control group, the positive control group using L-Tryptophan, and the experimental control group using MLCT or MFGM alone, the comparative model control group having p < 0.05, p < 0.01, and p < 0.001.
Fig. 2 presents the results of statistical analysis of total wakefulness time (a) and total wakefulness activity (B) of zebra fish in the normal control group, the model control group, the positive control group using L-Tryptophan, the experimental control group using MLCT or MFGM alone, and the experimental group using MLCT and MFGM in combination, as compared with the model control group in which p < 0.001 is expressed.
Detailed Description
In order to make the objects, technical solutions and advantageous technical effects of the present application more clear, the present application will be described in detail below. It should be noted that the various aspects, features, embodiments, and advantages thereof described herein may be compatible and/or may be combined together.
Unless defined otherwise, technical or scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.
In the present application, unless otherwise specified, the temperature is room temperature (25 ℃) and the atmosphere is air and the pressure is atmospheric pressure.
In the present application, the term "medium chain fatty acid" means fatty acids having 6 to 12 carbon atoms in the carbon chain, such as caproic acid, heptanoic acid, caprylic acid, nonanoic acid, capric acid, undecanoic acid, dodecanoic acid, etc., and the term "long chain fatty acid" means fatty acids having 14 or more carbon atoms, generally 14 to 30 carbon atoms in the carbon chain, such as myristic acid, palmitic acid, oleic acid, linoleic acid, stearic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid, etc. The terms "medium-chain fatty acid triglyceride" and "long-chain fatty acid triglyceride" refer to the esterification reaction products of "medium-chain fatty acid" and "long-chain fatty acid" with glycerol, respectively, and the term "medium-chain fatty acid triglyceride" refers to triglycerides containing both medium-chain fatty acid residues and long-chain fatty acid residues in the molecular structure.
In the present application, "special food" refers to special food for a specific group of people, for example, "one old and one young patient", and includes three types of health food, infant formula food and special medical formula food.
The present invention relates to nutritional compositions comprising MLCT and MFGM, to food and pharmaceutical products comprising the nutritional compositions, to the use of the nutritional compositions or the food products for non-therapeutic purposes for improving sleep, and to the use of the nutritional compositions for the manufacture of a pharmaceutical product for improving sleep. The present invention will be described in detail below.
Nutritional composition
The first aspect of the invention relates to a nutritional composition comprising medium-long chain fatty acid triglycerides (MLCT) and Milk Fat Globule Membranes (MFGM), wherein the weight ratio of MLCT to MFGM is from 0.1:1 to 50:1.
Among the components comprised in the nutritional composition of the invention, medium-long chain fatty acid triglycerides (MLCT) are a class of structural lipids containing both medium-chain and long-chain fatty acids on the triglyceride molecule, which have different physicochemical properties, metabolic characteristics and nutritional values than long-chain fatty acid triglycerides (LCT) or medium-chain fatty acid triglycerides (MCT). Studies (see for example Yuan Tinglan, medium-long chain triglyceride composition of the mother milk fat and its metabolic characteristics [ D ], university of south of the Yangtze river, 2021) show that medium-long chain fatty acid triglycerides (MLCT) are not simply equivalent to physical mixtures of long chain fatty acid triglycerides (LCT) and medium chain fatty acid triglycerides (MCT) (nor of course to simple mixtures of long chain fatty acids and medium chain fatty acids), the latter not possessing the physicochemical properties, metabolic characteristics and nutritional value of the former.
Among the components comprised in the nutritional composition of the present invention, the term "medium-long chain fatty acid triglyceride" or "MLCT" is a specific triglyceride in which both medium-chain fatty acids and long-chain fatty acids are present on the triglyceride backbone. According to the relevant regulations of new resource food management method, MLCT is prepared by taking edible vegetable oil and medium chain triglyceride as raw materials, performing transesterification reaction by lipase, and performing distillation separation, decolorization, deodorization and other processes.
Among the components comprised in the nutritional composition of the invention, "milk fat globule membrane" or "MFGM", english Milk Fat Globule Membrane is a complex biofilm structure present in breast milk. MFGM is a complex 3-layer phospholipid protein membrane composed of polar lipids, cholesterol, proteins, etc., encapsulated on the surface of milk fat droplets. The source of MFGM according to the present invention is not particularly limited in principle and may generally be obtained by extraction from animal milk or products thereof, which in some preferred embodiments may be cow milk, sheep milk, camel milk, horse milk or dairy products based thereon (e.g. cheese) or the like, more preferably may be extracted from cow milk, including cow colostrum or cow normal milk.
The method for extracting MFGM from the animal milk or the product thereof is not particularly limited, and for example, the MFGM may be isolated by an acidification precipitation-centrifugation-isoelectric enrichment-drying method, or by a conventional membrane filtration method.
The MFGM may be obtained by commercial products, including MFGM whey protein powder and MFGM whey protein powder. MFGM whey protein powder is a powdery product containing MFGM obtained by using raw milk or whey as a raw material and performing the steps of separation, concentration, drying and the like. MFGM milk protein powder is a powdery product containing MFGM, which is prepared from raw milk or cream by separating, concentrating, drying, etc.
Commercial sources of MFGM according to the invention include LacprodanMFGM-10、LacprodanPL-20、Cor-PowerSM2, lipid-rich MFGM fraction or buttermilk concentrate BPC50, BPC60, G600, PC700, hilmarCor-PowerWPC7500MEGM ENRICHED WPC, etc.
The inventors have unexpectedly found in the study that MLCT and MFGM when used in combination in a specific weight ratio exhibit a synergistic effect in improving sleep, in particular in terms of arousal activity and total arousal time, the effect of the combined use being superior to that of the same total amount of MLCT alone, as well as to that of the same total amount of MFGM alone.
The present invention is not particularly limited to the MLCT used, and the MLCT commonly used in the art can be used. The MLCT may be used in pure form or in a non-pure form enriched in MLCT.
In some embodiments, the MLCT's used in the present invention comprise C 6-C12 (e.g., C 6、C7、C8、C9、C10、C11、C12, or a range defined by any two thereof) and C 14-C30 (e.g., C14、C15、C16、C17、C18、C19、C20、C21、C22、C23、C24、C25、C26、C27、C28、C29、C30、, or a range defined by any two thereof) fatty acid residues, wherein the C 6-C12 fatty acid residues are derived from one or more of caproic acid, enanthic acid, caprylic acid, pelargonic acid, capric acid, undecanoic acid, lauric acid, and the like, preferably caproic acid, caprylic acid, capric acid, and lauric acid, and/or the C 14-C30 fatty acid residues are derived from one or more of myristic acid, palmitic acid, margaric acid, oleic acid, linoleic acid, stearic acid, nonadecanoic acid, eicosapentaenoic acid, heneicosanoic acid, docosahexaenoic acid, tricarbonic acid, tetracosanoic acid, eicosapentaenoic acid, hexaenoic acid, arachidonic acid, and the like, preferably myristic acid, palmitic acid, oleic acid, linoleic acid, linolenic acid, arachidonic acid, eicosapentaenoic acid, and docosahexaenoic acid.
In some embodiments, the weight ratio of the C 6-C12 fatty acid residues to the C 14-C30 fatty acid residues in the MLCT is 0.124 to 2.000. As an example, the weight ratio of the C 6-C12 fatty acid residues to the C 14-C30 fatty acid residues may be within a range defined by 0.124、0.125、0.130、0.140、0.150、0.160、0.170、0.180、0.190、0.200、0.300、0.400、0.500、0.600、0.700、0.800、0.900、1.000、1.100、1.200、1.300、1.400、1.500、1.600、1.700、1.800、1.900、2.000 or any two of them.
MFGM may be derived from any MFGM containing substance such as raw cow milk and/or raw sheep milk and/or whole milk powder and/or desalted whey powder and/or whey protein powder and/or concentrated whey protein powder (MFGM) and/or MFGM powder.
In an embodiment, in the nutritional composition of the invention, the weight ratio of the MLCT to the MFGM is from 0.1:1 to 50:1. When the weight ratio of the MLCT to the MFGM is within the above range, MFGM and MLCT exhibit a synergistic effect in improving sleep. As an example, the weight ratio of the MLCT to the MFGM may be 0.1:1、0.2:1、0.3:1、0.4:1、0.45:1、0.48:1、0.5:1、0.6:1、0.7:1、0.8:1、0.9:1、1:1、2:1、3:1、4:1、5:1、6:1、7:1、7.5:1、7.74:1、8:1、9:1、10:1、12:1、14:1、16:1、18:1、20:1、22:1、24:1、26:1、28:1、30:1、32:1、34:1、36:1、38:1、40:1、42:1、44:1、46:1、48:1、50:1 or within a range defined by any two of them.
Preferably, the weight ratio of the MLCT to the MFGM is from 0.2:1 to 40:1, and when the weight ratio of the MLCT to the MFGM is within this range, the synergistic effect of the MFGM and the MLCT in improving sleep, particularly the amount of wakefulness and the total time of wakefulness is more pronounced.
More preferably, the weight ratio of the MLCT to the MFGM is from 0.4:1 to 24:1, and when the weight ratio of the MLCT to the MFGM is within this range, the synergistic effect of the MFGM and the MLCT in improving sleep, particularly the amount of wakefulness and the total time of wakefulness is more pronounced.
It is further preferred that the weight ratio of the MLCT to the MFGM is from 0.4:1 to 8:1, and that the synergistic effect of the MFGM and the MLCT in improving sleep, particularly the amount of wakefulness and the total time of wakefulness, is more pronounced when the weight ratio of the MLCT to the MFGM is within this range.
Even more preferably, the weight ratio of the MLCT to the MFGM is from 1:1 to 5:1, and when the weight ratio of the MLCT to the MFGM is within this range, the synergistic effect of MFGM and MLCT in improving sleep, particularly the amount of wakefulness and the total time of wakefulness is more pronounced.
In some embodiments, the nutritional compositions of the invention may consist of a medium-long chain fatty acid ester and MFGM.
Food products
In a second aspect the invention provides a food product comprising a nutritional composition according to the first aspect of the invention.
In some embodiments, the food product may be, for example, a functional food, a health food, or a health food.
In some embodiments, the food product is an infant food product, such as an infant formula.
In some embodiments, the food product is a regular food product or a special food product. As an example, the food product may be selected from dairy products, candies, beverages, bread and biscuits, for example the food product may be selected from milk powder or fermented food products. In some embodiments, the milk powder is an infant formula.
In some embodiments, the MLCT content may be 0.1% to 30.0% based on the dry basis weight of the food (after moisture is subtracted). As an example, the MLCT content may be 0.1、0.15、0.2、0.25、0.3、0.35、0.4、0.45、0.5、0.55、0.6、0.65、0.7、0.75、0.8、0.85、0.9、0.95、1.0、1.5、2.0、2.5、3.0、3.5、4.0、4.5、5.0、5.5、6.0、6.5、7.0、7.5、8.0、8.5、9.0、9.5、10.0、10.5、11.0、11.5、12.0、12.5、13.0、13.5、14.0、14.5、15.0、15.5、16.0、16.5、17.0、17.5、18.0、18.5、19.0、19.5、20.0、20.5、21.0、21.5、22.0、22.5、23.0、23.5、24.0、24.5、25.0、25.5、26.0、26.5、27.0、27.5、28.0、28.5、29.0、29.5、30.0% by weight on a dry basis, or within a range defined by any two of them, based on the weight of the foodstuff. And in a further embodiment, the MFGM content is scaled.
In some embodiments, the MFGM content may be 0.1 to 30.0% based on the dry weight of the food product (after moisture subtraction). As an example, the MFGM content may be 0.1、0.15、0.2、0.25、0.3、0.35、0.4、0.45、0.5、0.55、0.6、0.65、0.7、0.75、0.8、0.85、0.9、0.95、1.0、1.5、2.0、2.5、3.0、3.5、4.0、4.5、5.0、5.5、6.0、6.5、7.0、7.5、8.0、8.5、9.0、9.5、10.0、10.5、11.0、11.5、12.0、12.5、13.0、13.5、14.0、14.5、15.0、15.5、16.0、16.5、17.0、17.5、18.0、18.5、19.0、19.5、20.0、20.5、21.0、21.5、22.0、22.5、23.0、23.5、24.0、24.5、25.0、25.5、26.0、26.5、27.0、27.5、28.0、28.5、29.0、29.5、30.0% by weight on a dry basis, or within a range defined by any two of them, based on the weight of the food product.
Here, the weight% based on the food may be based on the total weight of the food or may be based on the dry weight of the food.
Furthermore, it will be readily appreciated by a person skilled in the art that the food product may comprise, in addition to the nutritional composition of the first aspect of the invention, one or more selected from raw milk, desalted whey powder, concentrated whey protein, lactose, edible vegetable blend oil, fructooligosaccharides, galactooligosaccharides, nucleotides, choline, vitamins, minerals, DHA and taurine.
For example, when the food is milk powder, the milk powder may comprise proteins such as alpha-lactalbumin, MFGM, carbohydrates such as lactose, lipids, minerals such as calcium, iron, phosphorus, etc., vitamins, other additives such as whey powder, choline bitartrate, docosahexaenoic acid, arachidonic acid, walnut oil, etc., in addition to the nutritional composition according to the first aspect of the invention.
The food may be a powder, tablet or liquid.
The food product of the art may be produced using preparation methods commonly used in the art and will not be described in detail herein.
All the above description of the nutritional composition according to the first aspect of the invention applies here.
Medicine
A third aspect of the invention provides a pharmaceutical product comprising a nutritional composition according to the first aspect of the invention.
The invention has no special requirement on the dosage form of the medicine, and can adopt the dosage form of the medicine commonly used in the field. As examples, the pharmaceutical product of the present invention may be a solid preparation such as powder, granule, tablet, capsule, drop pill, etc., a semisolid preparation such as ointment, cream, eye ointment, gel, etc., a liquid preparation such as oral liquid preparation such as syrup, mixture, suspension, emulsion, etc.
Those skilled in the art will readily appreciate that the pharmaceutical product may also include pharmaceutically acceptable excipients, depending on the formulation of the pharmaceutical product, the application, etc. In addition, the pharmaceutical product of the present invention may be prepared by a method generally employed in the art, and will not be described herein.
All the above description of the nutritional composition according to the first aspect of the invention applies here.
Use of the same
A fourth aspect of the invention relates to the use of a nutritional composition according to the first aspect of the invention or a food product (e.g. a health food) according to the second aspect of the invention for non-therapeutic purposes for improving sleep.
The non-therapeutic purpose for improving sleep (non-medical therapeutic purpose such as nutritional and/or health purpose) is for example for preparing a food (e.g. a functional food, a health food, or a health food) for improving sleep.
In some embodiments, the improving sleep may include, for example, improving sleep quality in adults, adolescents, children, or infants, particularly in infants.
In some embodiments, the improving sleep comprises improving (e.g., reducing) the amount of arousal activity and the total time of arousal.
As described above, the MLCT and MFGM exhibit a synergistic effect in improving sleep, particularly in terms of the amount of wakefulness and the total time of wakefulness, when used in combination in a specific weight ratio, and the effect of the combined use thereof is superior to that of the same total amount of MLCT alone, and also to that of the same total amount of MFGM alone.
In embodiments, the nutritional composition or food (e.g., health food) when administered orally to a human, is administered at a dose such that the MLCT is administered at a dose of 0.1 to 30.0 g g/day, preferably 0.4 to 30 g/day (e.g., 0.1、0.15、0.2、0.25、0.3、0.35、0.4、0.45、0.5、0.55、0.6、0.65、0.7、0.75、0.8、0.85、0.9、0.95、1.0、1.5、2.0、2.5、3.0、3.5、4.0、4.5、5.0、5.5、6.0、6.5、7.0、7.5、8.0、8.5、9.0、9.5、10.0、10.5、11.0、11.5、12.0、12.5、13.0、13.5、14.0、14.5、15.0、15.5、16.0、16.5、17.0、17.5、18.0、18.5、19.0、19.5、20.0、20.5、21.0、21.5、22.0、22.5、23.0、23.5、24.0、24.5、25.0、25.5、26.0、26.5、27.0、27.5、28.0、28.5、29.0、29.5、30.0 g/ days, or a range defined by any two of them), and in further embodiments, the MFGM is administered at a dose scaled up.
In some embodiments, the MFGM may be administered at a dose of 0.1-30.0 g/day (e.g., 0.1、0.2、0.3、0.4、0.5、0.6、0.7、0.8、0.9、1.0、2.0、3.0、4.0、5.0、6.0、7.0、8.0、9.0、10.0、11.0、12.0、13.0、14.0、15.0、16.0、17.0、18.0、19.0、20.0、21.0、22.0、23.0、24.0、25.0、26.0、27.0、28.0、29.0、30.0 g/ days, or a range defined by any two of them).
A fifth aspect of the invention relates to the use of a nutritional composition according to the first aspect of the invention for the preparation of a medicament for improving sleep.
The improving sleep may include improving (e.g., reducing) the amount of wakefulness and the total time of wakefulness.
All the above description of the nutritional composition according to the first aspect of the invention applies here and will not be repeated here.
Examples
The present invention will be described in further detail with reference to the following examples in order to make the objects, technical solutions and advantages of the present invention more apparent. It should be understood that the specific embodiments described herein are for purposes of illustration only and are not intended to limit the scope of the invention.
The source and specification of the raw materials used in the following examples were MLCT using medium-long chain fatty acid edible oil (production lot number Y1505-22120101) produced by Qingdao Hirship Life technologies Co., ltd, wherein the purity of MLCT was 69.+ -.10 wt.%, milk Fat Globule Membrane (MFGM) purchased from Arla under the product name Lacprodan MFGM-10, lot P510216, the phospholipid content of the raw materials was 8.+ -.2 wt.%, the protein content was 71.5.+ -.5 wt.%, the sphingomyelin g/100g phospholipid was 25.+ -.10 g, and wild type strain AB zebra fish, supplied by Hangzhou Cyclot Biotech Co., ltd, L-Tryptophan (lot number 111521, shanghai Tao Shu Biotechnology Co., china), purity 99.87%, luzindole (lot number SLCM6972, sigma, USA), purity was not less than 90%).
Animal experiment
Wild type AB strain zebra fish 5 days after fertilization (5 dpf) were randomly selected in well plates, 30 zebra fish were treated per well, and 10 wells were repeated per group. Each experiment was set with a normal control group, a model control group, a positive control group, an experimental control group and an experimental group, respectively. The samples were given in water-soluble form (concentrations shown in FIG. 1, FIG. 2, table 1), and the positive control group L-Tryptophan 50.0.0. Mu.g/mL was given at a concentration of 3: 3 mL per well, while the normal control group and the model control group were set. After 1 day of treatment at 28 ℃,10 zebra fish per group were randomly selected and transferred into 96-well plates at 1 tail/200 μl/well. Each of the remaining experimental groups, except the normal control group, was given Luzindole (6.25 μg/mL) in water to establish a zebra fish insomnia model. The wakefulness and total wakefulness time of the zebra fish in 1 h were measured by a behavior analyzer, and the sleep improvement effect of the sample was evaluated based on the statistical analysis results of the above indicators. Statistical treatment results were expressed as mean ± Standard Error (SE, standard Error) (n=10). Statistical analysis was performed with SPSS26.0 software, p < 0.05 indicated that the differences were statistically significant.
1. Using MLCT or MFGM alone
Fig. 1 presents the results of statistical analysis of the wakefulness amounts (a and C) and the total wakefulness times (B and D) of zebra fish in the normal control group, the model control group, the positive control group using L-Tryptophan, and the experimental control group using MLCT or MFGM alone, wherein fig. 1A shows the results of the wakefulness amounts when MLCT is used alone at different concentrations, fig. 1B shows the results of the total wakefulness times when MLCT is used alone at different concentrations, fig. 1C shows the results of the wakefulness amounts when MFGM is used alone at different concentrations, and fig. 1D shows the results of the total wakefulness times when MFGM is used alone at different concentrations.
As can be seen from fig. 1, both MLCT or MFGM alone resulted in significantly reduced total wakefulness and wakefulness, relative to the model control group, indicating that both MLCT or MFGM alone had sleep improving effects.
For MLCT alone, the concentration was the lowest at 250. Mu.g/mL of wakefulness, the total wakefulness time at the concentration of 250. Mu.g/mL was significantly lower than that at the concentration of 172.5. Mu.g/mL in terms of total wakefulness time, and when the concentration was greater than 250. Mu.g/mL, i.e., at concentrations of 345. Mu.g/mL and 690. Mu.g/mL, the total wakefulness time was not significantly reduced compared to that at the concentration of 250. Mu.g/mL (P > 0.05). Thus, 250 μg/mL is the optimal concentration of MLCT in improving sleep direction.
For MFGM alone, at a concentration of 250 μg/mL, both the total wakefulness time and the total wakefulness activity decreased significantly compared to that at a concentration of 125 μg/mL, but not significantly as its concentration continues to increase, i.e., at concentrations of 500 μg/mL and 1000 μg/mL. Thus, the optimal concentration of MFGM in the direction of sleep improving efficacy is also 250 μg/mL.
2. Use of nutritional compositions including MLCT or MFGM
As the optimal concentration experimentally obtained above, nutritional compositions comprising different proportions of MLCT or MFGM at a concentration of 250 μg/mL were studied. The results are shown in table 1 and more intuitively in fig. 2.
Table 1 efficacy results of nutritional compositions for improving sleep (n=10)
Note that compared to the model control group, p < 0.001 is represented.
As can be seen in combination with table 1 and fig. 2, both the amount of wakefulness and the time to wakefulness of examples 1 to 9 are significantly reduced compared to the model control group, indicating that the nutritional composition including MLCT and MFGM has an efficacy of improving sleep.
Further, when the MLCT: MFGM is in the range of 0.2:1 (example 2) to 40:1 (example 8), the resulting wakefulness and wakefulness time are both smaller than those of the MLCT alone at the same concentration and smaller than those of the MFGM alone at the same concentration, indicating that the MLCT and the MFGM exhibit significant synergy in the above-described concentration ranges.
Further, when MLCT: MFGM was in the range of 0.48:1 (example 3) to 24:1 (example 7), the resulting wakefulness and wakefulness time were smaller compared to the other examples, indicating further enhancement of the synergy.
Further, when MLCT: MFGM was in the range of 0.48:1 (example 3) to 7.74:1 (example 6), the resulting wakefulness and wakefulness time were smaller compared to the other examples, indicating further enhancement of the synergy.
Further, when MLCT: MFGM is in the range of 1:1 (example 4) to 5:1 (example 5), the resulting wakefulness and wakefulness time are smaller compared to the other examples, indicating further enhancement of the synergy.
What has been described above is merely an exemplary embodiment of the present invention. It should be noted that modifications to the present invention may be made by those of ordinary skill in the art without departing from the inventive concepts herein, and such modifications are intended to fall within the scope of the present invention.
Claims (16)
1. A nutritional composition comprising:
medium-long chain fatty acid triglyceride, and
A milk fat globule membrane, which is made of a milk fat globule membrane,
Characterized in that the weight ratio of the medium-long chain fatty acid triglyceride to the milk fat globule membrane is between 0.2:1 and 40:1.
2. Nutritional composition according to claim 1, characterized in that the weight ratio of the medium-long chain fatty acid triglyceride to the milk fat globule membrane is 0.4:1 to 24:1.
3. Nutritional composition according to claim 1, characterized in that the weight ratio of the medium-long chain fatty acid triglyceride to the milk fat globule membrane is 0.4:1 to 8:1.
4. Nutritional composition according to claim 1, characterized in that the weight ratio of the medium-long chain fatty acid triglyceride to the milk fat globule membrane is 1:1 to 5:1.
5. Food product, characterized in that it comprises a nutritional composition according to any one of claims 1-4.
6. Food product according to claim 5, characterized in that the food product is an infant food product.
7. Food product according to claim 5, characterized in that the food product is selected from the group consisting of dairy products, candies, beverages, bread and biscuits.
8. Food product according to claim 5, characterized in that the food product is a milk powder or a fermented food product.
9. Food product according to claim 8, characterized in that the milk powder is an infant formula.
10. Food product according to claim 5, characterized in that the food product is a health food product.
11. Food product according to any one of claims 5-10, characterized in that it further comprises one or more selected from raw milk, desalted whey powder, concentrated whey protein, lactose, edible vegetable blend oil, fructooligosaccharides, galactooligosaccharides, nucleotides, choline, vitamins, minerals, DHA and taurine.
12. Pharmaceutical product, characterized in that it comprises a nutritional composition according to any one of claims 1-4.
13. Use of the nutritional composition according to any one of claims 1-4 or the food according to any one of claims 5-11 for non-therapeutic purposes of improving sleep.
14. Use according to claim 13, characterized in that the sleep improvement is an improvement in the sleep of infants.
15. Use according to claim 13, characterized in that said improving sleep comprises improving the amount of wakefulness and the total time of wakefulness.
16. Use of a nutritional composition according to any one of claims 1-4 in the manufacture of a medicament for improving sleep.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202510308140.3A CN119817811B (en) | 2025-03-17 | 2025-03-17 | Nutritional composition and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202510308140.3A CN119817811B (en) | 2025-03-17 | 2025-03-17 | Nutritional composition and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN119817811A CN119817811A (en) | 2025-04-15 |
| CN119817811B true CN119817811B (en) | 2025-06-10 |
Family
ID=95309465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510308140.3A Active CN119817811B (en) | 2025-03-17 | 2025-03-17 | Nutritional composition and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN119817811B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102665428A (en) * | 2009-12-08 | 2012-09-12 | 雀巢产品技术援助有限公司 | Infant formula with probiotics and milk fat globule membrane components |
| CN118592494A (en) * | 2024-08-05 | 2024-09-06 | 内蒙古蒙牛乳业（集团）股份有限公司 | Application of oil composition in improving temperament of infants or children |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2259885B1 (en) * | 2004-09-29 | 2007-11-01 | Laboratorios Ordesa, S.L. | KIDS NUTRITIONAL KIT TO REGULATE THE DREAM-VIGILIA CYCLE. |
| EP2554166B1 (en) * | 2010-03-31 | 2019-08-28 | The Nisshin OilliO Group, Ltd. | Oil and fat composition for the treatment of diabetes |
| EP2452571A1 (en) * | 2010-11-15 | 2012-05-16 | Nestec S.A. | Array of complementary infant/young child nutritional compositions |
| CN103155999B (en) * | 2011-12-16 | 2015-08-26 | 光明乳业股份有限公司 | A kind of nutrient modularization baby milk powder and feedstock composition thereof |
| JP2019156774A (en) * | 2018-03-14 | 2019-09-19 | 日清オイリオグループ株式会社 | Drowsiness inhibitor, drowsiness inhibitory pharmaceutical composition, and drowsiness inhibitory food composition |
| CN111990462A (en) * | 2020-08-18 | 2020-11-27 | 黑龙江省完达山乳业股份有限公司 | Infant formula containing protein composition and preparation method thereof |
| US20250025491A1 (en) * | 2021-11-30 | 2025-01-23 | Mjn U.S. Holdings Llc | Uses of compositions comprising a prebiotic component |
| CN119157265A (en) * | 2024-09-11 | 2024-12-20 | 宁波大学 | Composition and application for regulating intestinal flora and lipid absorption in early life |
-
2025
- 2025-03-17 CN CN202510308140.3A patent/CN119817811B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102665428A (en) * | 2009-12-08 | 2012-09-12 | 雀巢产品技术援助有限公司 | Infant formula with probiotics and milk fat globule membrane components |
| CN118592494A (en) * | 2024-08-05 | 2024-09-06 | 内蒙古蒙牛乳业（集团）股份有限公司 | Application of oil composition in improving temperament of infants or children |
Also Published As
| Publication number | Publication date |
|---|---|
| CN119817811A (en) | 2025-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5616066B2 (en) | Human lipid composition and methods for making and using the same | |
| TWI230607B (en) | Pharmaceutical compositions for reducing the incidence of necrotizing enterocolitis | |
| TWI722992B (en) | Brain function improving agent, and preventive or therapeutic agent for cognitive dysfunction | |
| JPWO2008081934A1 (en) | Infant brain development promoter containing milk-derived phospholipid and food composition containing the same | |
| CN102740865A (en) | Mitochondrial function improver | |
| EP1803358A1 (en) | Infant immunological formula | |
| JPH09194362A (en) | Composition consisting of phospholipid containing docosahexanenoic acid and eicosapentanenoic acid | |
| JPH10101568A (en) | Improving medicine for cerebral function, and nutritient composition | |
| WO2015059697A1 (en) | Compositions comprising choline and derivatives thereof, uses thereof and processes for their preparation | |
| WO2008081989A1 (en) | Nerve regeneration agent | |
| CN119817811B (en) | Nutritional composition and use thereof | |
| CA3000103C (en) | Process for the preparation and stabilization of emulsions with omega-3 by means of isometric crystalline networks of cellulose derivatives | |
| CN119896330B (en) | Nutritional composition and use of a nutritional composition | |
| EP2572593B1 (en) | Compositions of human lipids and methods of making and using same | |
| CN119817812B (en) | Nutritional composition and use of a nutritional composition | |
| HK1255895A1 (en) | Composition for inhibiting migration of endotoxin into blood | |
| Kiruthika | Docosahexaenoic Acid (Dha)–The Magic of Master Brain | |
| JPS63237759A (en) | Food for treatment | |
| HK1230931A1 (en) | Brain function improving agent, and prophylactic or therapeutic agent for cognitive dysfunction | |
| HK1186353B (en) | Compositions of human lipids and methods of making and using same | |
| HK1136166B (en) | Compositions of human lipids and methods of making and using same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |